6 Related NICE guidance
Details are correct at the time of publication. Further information is available on the NICE website.
-
Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance 294 (2013).
-
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 283 (2013).
-
Ranibizumab for the treatment of diabetic macular oedema (rapid review of TA237). NICE technology appraisal guidance 274 (2013).
-
Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. NICE technology appraisal guidance 271 (2013).
-
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 229 (2011).
-
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155 (2008).
-
Guidance on the use of photodynamic therapy for age-related macular degeneration. NICE technology appraisal guidance 68 (2003).